Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
View through CrossRef
<p>Figure S1A. Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B. Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C. Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D. Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E. Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F. Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A. Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B. Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C. Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>
American Association for Cancer Research (AACR)
Title: supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Description:
<p>Figure S1A.
Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B.
Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C.
Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D.
Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E.
Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F.
Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A.
Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B.
Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C.
Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>.
Related Results
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
<div>Abstract<p>Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumo...
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract
The past decade has been a period of tremendous progress in the area of cancer immunotherapy. The field has progressed from a point where very modest subset...
Construction of competing endogenous RNA interaction networks as prognostic markers in metastatic melanoma
Construction of competing endogenous RNA interaction networks as prognostic markers in metastatic melanoma
AbstractMalignant melanoma (MM) is a highly aggressive, metastatic cancer originating from melanocytes. These tumors have an extremely poor prognosis. MM accounts for 4% of skin ca...
Abstract 1275: Quantitative proteomic analysis of tumor growth associated proteins in cutaneous malignant melanoma
Abstract 1275: Quantitative proteomic analysis of tumor growth associated proteins in cutaneous malignant melanoma
Abstract
BACKGROUND: The identification of proteins responsible for tumor development and regulation is of great value. In this study, we aimed to identify novel fun...
Precursors of skin melanoma (melanoma-sensitive nevi)
Precursors of skin melanoma (melanoma-sensitive nevi)
Interest in melanoma precursors, or melanoma-sensitive skin nevi, has not lost its relevance for many years due to the steady increase of skin melanoma morbidity in recent decades ...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis
Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis
Abstract
Background
Patients who present with palpable inguinal melanoma nodal metastasis have two surgical options: inguinal or...
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.
10007 Background: Metastatic mucosal melanoma responds poorly to PD-1 blockade therapy in comparison with cutaneous melanoma. Vascular endothelial growth factor (VEGF) is indicate...